- Home
- JOBY vs BLCO Comparison
JOBY vs BLCO Comparison
Compare JOBY & BLCO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- JOBY
- BLCO
- Stock Information
- Founded
- JOBY 2009
- BLCO 1853
- Country
- JOBY United States
- BLCO Canada
- Employees
- JOBY N/A
- BLCO N/A
- Industry
- JOBY Aerospace
- BLCO Ophthalmic Goods
- Sector
- JOBY Consumer Discretionary
- BLCO Health Care
- Exchange
- JOBY Nasdaq
- BLCO Nasdaq
- Market Cap
- JOBY 6.1B
- BLCO 6.3B
- IPO Year
- JOBY N/A
- BLCO 2022
- Fundamental
- Price
- JOBY $9.06
- BLCO $17.17
- Analyst Decision
- JOBY Strong Buy
- BLCO Buy
- Analyst Count
- JOBY 5
- BLCO 12
- Target Price
- JOBY $9.30
- BLCO $20.73
- AVG Volume (30 Days)
- JOBY 17.5M
- BLCO 396.1K
- Earning Date
- JOBY 02-19-2025
- BLCO 02-19-2025
- Dividend Yield
- JOBY N/A
- BLCO N/A
- EPS Growth
- JOBY N/A
- BLCO N/A
- EPS
- JOBY N/A
- BLCO N/A
- Revenue
- JOBY $1,113,000.00
- BLCO $4,684,000,000.00
- Revenue This Year
- JOBY N/A
- BLCO $17.32
- Revenue Next Year
- JOBY $8,570.53
- BLCO $5.98
- P/E Ratio
- JOBY N/A
- BLCO N/A
- Revenue Growth
- JOBY N/A
- BLCO 18.01
- 52 Week Low
- JOBY $4.50
- BLCO $13.16
- 52 Week High
- JOBY $10.72
- BLCO $21.69
- Technical
- Relative Strength Index (RSI)
- JOBY 55.98
- BLCO 35.11
- Support Level
- JOBY $7.73
- BLCO $17.00
- Resistance Level
- JOBY $10.72
- BLCO $17.57
- Average True Range (ATR)
- JOBY 0.71
- BLCO 0.45
- MACD
- JOBY -0.10
- BLCO -0.00
- Stochastic Oscillator
- JOBY 44.31
- BLCO 22.80
About JOBY Joby Aviation Inc.
Joby Aviation Inc is a transportation company developing electric air taxis for commercial passenger service.
About BLCO Bausch + Lomb Corporation
Bausch & Lomb is one of the largest vision care companies in the US. The firm was previously a subsidiary under parent company Bausch Health and it was spun off to become a public company in 2022. It operates in three segments: vision care, surgical, and ophthalmic pharmaceuticals. Vision care is composed of contact lenses, a market that B&L controls 10%, and ocular health products, which includes Biotrue and Lumify. Surgical includes a suite of intraocular lenses, equipment for cataract and vitreoretinal surgeries, as well as surgical instruments. Ophthalmic pharmaceuticals has a diverse lineup of products, including Xipere, Vyzulta, and Lotemax that treat different complications. With over 100 products, B&L has the largest portfolio of eye care prescriptions in the space.